A Phase II Trial of mTORC1/2 Inhibition in STK11 Deficient Non Small Cell Lung Cancer

In arm B2 of the National Lung Matrix Trial 54 patients with NSCLC received vistusertib, of which 49 were STK11-deficient. Objective response and durable clinical benefit rates with 95% credible intervals were estimated from posterior probability distributions generated using Bayesian beta-binomial conjugate analysis.